Ipsen: New Target Increase to 155 Euros at Closing
Ipsen's stock fell 1.22% on Wednesday, closing at 137.70 euros after reaching 139.40 euros the day before. Nevertheless, the pharmaceutical company's stock is still up 15.23% over three months and 13.71% over a year. In this context, analysts are adjusting their targets.
Significant Target Revision by Deutsche Bank
This Wednesday, Deutsche Bank significantly raised its target price on Ipsen, from 135 euros to 155 euros, while maintaining a 'buy' recommendation. This increase gives the stock a potential upside of about 12.5% compared to the last recorded price. Concurrently, BNP Paribas Exane also revised its approach two days earlier, on January 26, raising its target from 105 to 115 euros. However, the bank maintains an 'underperform' rating, reflecting a more cautious stance on the stock. These adjustments indicate an ongoing reevaluation of the potential of the group, which specializes in neuroscience and oncology, as the recent stock performance shows a marked upward trend.
Technical Analysis Indicates Strong Momentum
Technically, Ipsen is significantly above its 20-day moving average, set at 129.08 euros, indicating favorable momentum. The stock thus shows a premium of nearly 7% compared to this intermediate threshold. However, the 14-day Relative Strength Index (RSI) is in the overbought zone at 79, a level suggesting a short-term overheating and could limit the immediate progress of the stock. This situation reflects strong investor enthusiasm but also calls for caution regarding potential corrective movements. The one-month volatility stands at 9.35, reflecting moderate fluctuations in a generally upward-oriented context.
